Quercetin-3-methyl ether inhibits lapatinib-sensitive and -resistant breast cancer cell growth by inducing G2/M arrest and apoptosis

Molecular Carcinogenesis

Volumn 52, Issue 2, 2013, Pages 134-143

  Li, Jixia ^a,b   Zhu, Feng ^a   Lubet, Ronald A ^c   De Luca, Antonella ^f   Grubbs, Clinton ^d   Ericson, Marna E ^e   D'Alessio, Amelia ^f   Normanno, Nicola ^f   Dong, Zigang ^a   Bode, Ann M ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Apoptosis; Breast cancer; HER2; Lapatinib; Natural product; Quercetin 3 methyl ether

Indexed keywords

CASPASE 3; CASPASE 7; CHECKPOINT KINASE 1; CYCLIN B1; CYCLIN D1; LAPATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN KINASE B; QUERCETIN 3 METHYL ETHER;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOACCUMULATION; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL PROLIFERATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DEPHOSPHORYLATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

APOPTOSIS; BREAST NEOPLASMS; CASPASE 3; CASPASE 7; CDC2 PROTEIN KINASE; CDC25 PHOSPHATASES; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN B1; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; MAP KINASE SIGNALING SYSTEM; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; QUERCETIN; QUINAZOLINES; SIGNAL TRANSDUCTION;

EID: 84872612639     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21839     Document Type: Article

References (35)

1. Germano S, O'Driscoll L. Breast cancer: Understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicine. Curr Cancer Drug Targets 2009; 9: 398-418.
2. Mukohara T. Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer. Cancer Sci 2011; 102: 1-8.
3. Jeong JH, An JY, Kwon YT, Li LY, Lee YJ. Quercetin-induced ubiquitination and down-regulation of Her-2/neu. J Cell Biochem 2008; 105: 585-595.
4. Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011; 128: 347-356.
5. Blackwell KL, Pegram MD, Tan-Chiu E, et al. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol 2009; 20: 1026-1031.
6. Giampaglia M, Chiuri VE, Tinelli A, De Laurentiis M, Silvestris N, Lorusso V. Lapatinib in breast cancer: Clinical experiences and future perspectives. Cancer Treat Rev 2010; 36: S72-S79.
7. Duffy MJ, O'Donovan N, Crown J. Use of molecular markers for predicting therapy response in cancer patients. Cancer Treat Rev 2011; 37: 151-159.
8. Zoppoli G, Moran E, Soncini D, et al. Ras-induced resistance to lapatinib is overcome by MEK inhibition. Curr Cancer Drug Targets 2010; 10: 168-175.
9. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743.
10. Rubio S, Quintana J, Eiroa JL, Triana J, Estevez F. Acetyl derivative of quercetin 3-methyl ether-induced cell death in human leukemia cells is amplified by the inhibition of ERK. Carcinogenesis 2007; 28: 2105-2113.
11. Rubio S, Quintana J, Lopez M, Eiroa JL, Triana J, Estevez F. Phenylbenzopyrones structure-activity studies identify betuletol derivatives as potential antitumoral agents. Eur J Pharmacol 2006; 548: 9-20.
12. Lee EH, Kim HJ, Song YS, et al. Constituents of the stems and fruits of Opuntia ficus-indica var. saboten. Arch Pharm Res 2003; 26: 1018-1023.
13. Takeara R, Albuquerque S, Lopes NP, Lopes JL. Trypanocidal activity of Lychnophora staavioides Mart. (Vernonieae, Asteraceae). Phytomedicine 2003; 10: 490-493.
14. Wei BL, Lu CM, Tsao LT, Wang JP, Lin CN. In vitro anti-inflammatory effects of quercetin 3-O-methyl ether and other constituents from Rhamnus species. Planta Med 2001; 67: 745-747.
15. Colburn NH, Wendel EJ, Abruzzo G. Dissociation of mitogenesis and late-stage promotion of tumor cell phenotype by phorbol esters: Mitogen-resistant variants are sensitive to promotion. Proc Natl Acad Sci USA 1981; 78: 6912-6916.
16. De Luca A, Faraso S, D'Alessio A, et al. Characterization of human breast cancer cells with acquired resistance to the EGFR/ErbB-2 tyrosine kinase inhibitor lapatinib. AACR 102nd Annual Meeting 2011. 2011; Abstract no. 3581.
17. Eastman A. Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J Cell Biochem 2004; 91: 223-231.
18. Holmes JK, Solomon MJ. A predictive scale for evaluating cyclin-dependent kinase substrates. A comparison of p34cdc2 and p33cdk2. J Biol Chem 1996; 271: 25240-25246.
19. Lobrich M, Jeggo PA. The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat Rev Cancer 2007; 7: 861-869.
20. Brunner-Kubath C, Shabbir W, Saferding V, et al. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast Cancer Res Treat 2011; 129: 387-400.
21. D'Alessio A, De Luca A, Maiello MR, et al. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells. Breast Cancer Res Treat 2010; 123: 387-396.
22. Deep G, Singh RP, Agarwal C, Kroll DJ, Agarwal R. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: A comparison of flavanone silibinin with flavanolignan mixture silymarin. Oncogene 2006; 25: 1053-1069.
23. DePinto W, Chu XJ, Yin X, et al. In vitro and in vivo activity of R547: A potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol Cancer Ther 2006; 5: 2644-2658.
24. Ye Z, Chen Z, Chen W, et al. XJW20, a novel oxoindole derivative, induces G2/M arrest and apoptosis selectively in K562 leukemia cell line. Chem Biol Interact 2010; 183: 133-141.
25. Aguda BD. A quantitative analysis of the kinetics of the G(2) DNA damage checkpoint system. Proc Natl Acad Sci USA 1999; 96: 11352-11357.
26. Furnari B, Rhind N, Russell P. Cdc25 mitotic inducer targeted by chk1 DNA damage checkpoint kinase. Science 1997; 277: 1495-1497.
27. Chu I, Blackwell K, Chen S, Slingerland J. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 2005; 65: 18-25.
28. Choi EJ, Kim GH. Apigenin causes G(2)/M arrest associated with the modulation of p21(Cip1) and Cdc2 and activates p53-dependent apoptosis pathway in human breast cancer SK-BR-3 cells. Nutr Biochem 2009; 20: 285-290.
29. Yu J, Zhang L. Apoptosis in human cancer cells. Curr Opin Oncol 2004; 16: 19-24.
30. Kliem H, Berisha B, Meyer HH, Schams D. Regulatory changes of apoptotic factors in the bovine corpus luteum after induced luteolysis. Mol Reprod Dev 2009; 76: 220-230.
31. Germain M, Affar EB, D'Amours D, Dixit VM, Salvesen GS, Poirier GG. Cleavage of automodified poly(ADP-ribose) polymerase during apoptosis. Evidence for involvement of caspase-7. J Biol Chem 1999; 274: 28379-28384.
32. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994; 371: 346-347.
33. Wang Y, Decker SJ, Sebolt-Leopold J. Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther 2004; 3: 305-313.
34. Chen CY, Hsu YL, Tsai YC, Kuo PL. Kotomolide A arrests cell cycle progression and induces apoptosis through the induction of ATM/p53 and the initiation of mitochondrial system in human non-small cell lung cancer A549 cells. Food Chem Toxicol 2008; 46: 2476-2484.
35. Sahu RP, Batra S, Srivastava SK. Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells. Br J Cancer 2009; 100: 1425-1433.